The Community Focus Channel is supported with funding from Johnson & Johnson (Gold).
The Multiple Myeloma Channel is supported with funding from AbbVie (Platinum), Sanofi (Gold), Legend Biotech (Bronze), and through an educational grant from Alexion Pharma GmbH.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
General Updates | Insights into what to expect at the 2026 MYELOMAS meeting
Claudio Cerchione, MD, PhD, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy, shares insight into his upcoming MYELOMAS meeting in Rome, Italy, highlighting a session on the new state-of-the-art frontline treatment in multiple myeloma, highlighting the potential of quadruplet therapies as a standard of care, and the importance of sustained measurable residual disease (MRD) negativity as an endpoint for cure. This interview took place virtually.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
